Cargando…
New Antiviral Agents for Hepatitis C
Approximately 120-130 million individuals are chronically infected with hepatitis C virus (HCV) worldwide, although it is curable by therapy. Until recently, treatment of chronic hepatitis C was based on the combination of pegylated interferon-α and ribavirin. A number of models have been developed...
Autor principal: | Pawlotsky, Jean-Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292288/ https://www.ncbi.nlm.nih.gov/pubmed/22403588 http://dx.doi.org/10.3410/B4-5 |
Ejemplares similares
-
What are the pros and cons of the use of host-targeted agents against hepatitis C?
por: Pawlotsky, Jean-Michel
Publicado: (2014) -
Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016) -
Hepatitis C and renal transplantation in era of new antiviral agents
por: Salvadori, Maurizio, et al.
Publicado: (2018) -
Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention
por: Ahmed-Belkacem, Abdelhakim, et al.
Publicado: (2014) -
Hepatitis C Virus Serologic and Virologic Tests and Clinical Diagnosis of HCV-Related Liver Disease
por: Chevaliez, Stéphane, et al.
Publicado: (2006)